1.恒瑞2024Q3 财报:前三季度营收201.89亿元,同比增长18.67%10月24日晚,恒瑞医药公布2024年三季度业绩报告,公司业绩稳健增长:前三季度恒瑞医药实现营业收入201.89亿元,同比增18.67%,归属于上市公司股东的净利润46.20亿元,同比增32.98%,归属于上市公司股东的扣除非经常性损益的净利润46.16亿元,同比增37.38%。报告显示,2024年前三季度研发费用达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.